Medicine for treating I-type hypersensitivity

Through the binding of tetrahedral framework nucleic acid and targeted siRNA, the degranulation of mast cells in type I hypersensitivity reaction is inhibited, and the problem of inhibiting mast cells in the prior art is solved, and effective control of type I hypersensitivity reaction is achieved.

CN118955595AActive Publication Date: 2024-11-15SICHUAN UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411024830.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-15
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit the degranulation process of mast cells in type I hypersensitivity reactions, resulting in the persistent risk of severe allergic reactions in some patients.

Method used

The tetrahedral framework nucleic acid is used to bind to siRNA targeted to inhibit Gab2 and Syk expression, and self-assemble the complex TSS through heating and cooling reactions to inhibit the degranulation process of mast cells.

Benefits of technology

Complex TSS can effectively inhibit the degranulation of mast cells, stabilize mitochondrial energy metabolism, reduce symptoms of allergic reactions, and have broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955595A_ABST
    Figure CN118955595A_ABST
Patent Text Reader

Abstract

The invention provides a medicine for treating I-type hypersensitivity, and belongs to the field of pharmacy. The tetrahedral framework nucleic acid can effectively inhibit mast cell degranulation, can stabilize the mitochondrial energy metabolism level, recovers mitochondrial membrane potential reduction and metabolic change caused by allergy excitation, and effectively inhibits I-type hypersensitivity in vivo. According to the invention, siRNA targeting Gab2 and Syk is further modified on the basis of tetrahedral framework nucleic acid, so that the compound TSS is obtained. The compound TSS can stabilize energy metabolism of mitochondria, inhibit exocytosis of calcium ions in the mitochondria, inhibit degranulation of mast cells and play a role in inhibiting I-type hypersensitivity. Particularly, it is worthy of noting that the compound TSS plays a synergistic role in inhibiting the I-type hypersensitivity reaction. The tetrahedral framework nucleic acid and the compound TSS are simple to synthesize and stable in structure, and have wide application prospects in preparation of drugs for preventing and / or treating type I hypersensitivity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceuticals, and in particular relates to a medicine for treating type I hypersensitivity reaction. Background Art

[0002] Hypersensitivity reactions can be divided into four types according to the Gail-Coombs classification. Type I hypersensitivity reactions are the most common type, and the term allergy usually refers to this type. It is estimated that 20%-30% of the population suffers from allergic diseases such as asthma, food allergies, allergic rhinitis, allergic conjunctivitis, urticaria, angioedema, and anaphylactic shock. Its incidence is on the rise worldwide, and it also imposes a huge burden on the economy. It is reported that in 2013, the total cost of asthma alone in the United States among allergic diseases was as high as 81.9 billion US dollars. Allergic diseases have a serious negative impact on the quality of human life.

[0003] The occurrence of type I hypersensitivity reaction is a complex immune response process. After contact with external antigens, B cells will produce corresponding immunoglobulin E (IgE), which will then bind to the IgE high affinity receptor (FcεRI) on mast cells. At this time, mast cells are in a sensitized state. When exposed to the same antigen again, mast cells will quickly degranulate and release multiple factors such as histamine, trypsin-like enzymes, leukotrienes, tumor necrosis factor α (TNF-α), leading to increased vascular permeability, muscle spasms, and increased glandular secretions. Mast cells are widely distributed in the skin, mucous membranes, gastrointestinal tract, glands, and around nerves and blood vessels, so degranulation can cause various allergic symptoms. Mast cells are the key link in the occurrence of type I hypersensitivity reactions, and their degranulation process includes two stages. First, the particles away from the cell membrane will be transported to the cell membrane through microtubules, and then the particles will fuse with the cell membrane and release their contents to the outside of the cell. These two stages are controlled by the Fyn / Gab2 and Lyn / Syk pathways, respectively. Therefore, developing drugs that can effectively inhibit mast cell degranulation is an important direction for the development of drugs for the treatment of type I hypersensitivity reactions.

[0004] At present, most patients can control type I hypersensitivity to a certain extent by avoiding allergen contact, receiving traditional allergen-specific immunotherapy (AIT) and symptomatic drug treatment; however, a small number of patients still have persistent symptoms and are at risk of life-threatening allergic reactions. It is of great significance to develop new drugs that can effectively and safely treat type I hypersensitivity reactions. Summary of the invention

[0005] In order to solve the defects of the prior art, the object of the present invention is to provide a drug for treating type I hypersensitivity reaction.

[0006] The present invention provides a tetrahedral framework nucleic acid, which is self-assembled by four DNA single strands, and the sequences of the four DNA single strands are shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 respectively.

[0007] The present invention also provides a method for preparing the tetrahedral framework nucleic acid, which comprises the following steps: mixing four DNA single strands, heating them for reaction, and then cooling them for reaction, so as to obtain the tetrahedral framework nucleic acid.

[0008] Furthermore, the heating reaction temperature is 80-100°C and the time is 5-15min;

[0009] The temperature of the cooling reaction is 0-10°C and the time is 10-30min;

[0010] Preferably, the heating reaction temperature is 95°C and the time is 10 minutes;

[0011] The temperature of the cooling reaction is 4°C and the time is 20 minutes.

[0012] The present invention also provides a tetrahedral framework nucleic acid complex, which is a product prepared by using a reagent for inhibiting mast cell degranulation and the above tetrahedral framework nucleic acid as raw materials.

[0013] Furthermore, the agent for inhibiting mast cell degranulation is an agent for targeted inhibition of Gab2 and / or Syk expression.

[0014] Furthermore, the reagent for targeted inhibition of Gab2 expression is a siRNA for targeted inhibition of Gab2 expression, and the siRNA for targeted inhibition of Gab2 expression is composed of two single strands whose sequences are shown in SEQ ID NO.5 and SEQ ID NO.6 respectively through base complementary pairing;

[0015] The reagent for targeted inhibition of Syk expression is siRNA for targeted inhibition of Syk expression, and the siRNA for targeted inhibition of Syk expression is formed by two single strands with sequences as shown in SEQ ID NO.7 and SEQ ID NO.8 respectively through base complementary pairing.

[0016] Furthermore, the reagent for inhibiting mast cell degranulation is a reagent for targeted inhibition of Syk expression and a reagent for targeted inhibition of Gab2 expression, and the molar ratio of the reagent for targeted inhibition of Syk expression, the reagent for targeted inhibition of Gab2 expression, and the tetrahedral framework nucleic acid is 1:1:(0.1-1), preferably 1:1:0.5.

[0017] The present invention also provides a method for preparing the above tetrahedral framework nucleic acid complex, which comprises the following steps: mixing a reagent for inhibiting mast cell degranulation with a tetrahedral framework nucleic acid, first heating the mixture for reaction, and then cooling the mixture for reaction, thereby obtaining the tetrahedral framework nucleic acid complex.

[0018] Furthermore, the heating reaction temperature is 80-100°C and the time is 5-15min;

[0019] The temperature of the cooling reaction is 0-10°C and the time is 10-30min;

[0020] Preferably, the heating reaction temperature is 95°C and the time is 10 minutes;

[0021] The temperature of the cooling reaction is 4°C and the time is 20 minutes.

[0022] The present invention also provides the use of the tetrahedral framework nucleic acid and the tetrahedral framework nucleic acid complex in preparing a drug for preventing and / or treating type I hypersensitivity reaction.

[0023] Furthermore, the drug is a pharmaceutical preparation prepared with the tetrahedral framework nucleic acid or tetrahedral framework nucleic acid complex as an active ingredient and pharmaceutically acceptable excipients.

[0024] Furthermore, the drug is a drug that inhibits mast cell degranulation.

[0025] The present invention has achieved the following beneficial effects:

[0026] 1. The tetrahedral framework nucleic acid provided by the present invention can effectively inhibit the degranulation of RBL-2H3 cells when administered alone, stabilize the mitochondrial energy metabolism level, restore the decreased mitochondrial membrane potential and metabolic changes caused by allergic stimulation, and effectively inhibit type I hypersensitivity reactions in vivo. It has broad application prospects in the preparation of drugs for preventing and / or treating type I hypersensitivity reactions.

[0027] 2. The present invention further modifies siRNA targeting Gab2 and Syk on the basis of tetrahedral framework nucleic acid to obtain complex TSS. Complex TSS can carry siRNA into cells to exert RNA interference (RNA interference, RNAi) and is used to treat type I hypersensitivity. In the RBL-2H3 cell model induced by anti-DNP-IgE and DNP-BSA, after siRNA targeting Gab2 and Syk enters the cell, it inhibits the two pathways of Fyn / Gab2 and Lyn / Syk and downstream targets, and inhibits the occurrence of mast cell degranulation. The complex TSS of the present invention can stabilize mitochondrial energy metabolism, inhibit the efflux of calcium ions in mitochondria into cells, and further inhibit the occurrence of mast cell degranulation. In the mouse passive skin allergy model, the complex TSS of the present invention can enter the mouse body through intraperitoneal injection and transdermal administration, inhibit mast cell degranulation through multi-pathway administration, reduce swelling and inflammation caused by increased local vascular permeability, and play a role in inhibiting type I hypersensitivity. It is particularly noteworthy that the complex TSS plays a synergistic role in inhibiting type I hypersensitivity. The composite TSS of the present invention is not only simple to synthesize and has a stable structure, but also has excellent multi-pathway drug delivery potential and broad application prospects.

[0028] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0029] The above contents of the present invention are further described in detail below through specific implementation methods in the form of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Experimental results for the synthesis, validation and characterization of tetrahedral framework nucleic acids (TSSs) modified with siRNA targeting Gab2 and Syk (A: the synthesis process of TSS; B: the high-performance capillary electrophoresis test results of tFNAs; C: the polyacrylamide gel electrophoresis test results of tFNAs; D: the dynamic light scattering test results of TSS; E: the transmission electron microscopy test results of TSS; F: the atomic force microscopy test results of TSS; G: the stability of TSS in cell lysate; H: the stability of TSS in serum; I: the stability of TSS under -4°C storage conditions).

[0031] Figure 2The experimental results of TSS entry into cells and RNA interference (A: the process of TSS entering cells and exerting RNAi effects; B: laser confocal microscopy test of siRNA being carried into cells by tFNAs; C: flow cytometry detection of TSS; D: cell activity test of TSS; E: WB detection of TSS effect on Gab2 expression; F: WB detection of TSS effect on Syk expression; G: qPCR detection of TSS effect on Gab2 and Syk expression; H: immunofluorescence detection of TSS effect on Gab2 expression; I: immunofluorescence detection of TSS effect on Syk expression).

[0032] Figure 3 The experimental results of TSS inhibiting the degranulation of RBL-2H3 cells (A: cell morphology after toluidine blue staining; B: cell morphology under scanning electron microscope; C: cell apoptosis under fluorescence detection; D: calcium ion concentration under fluorescence detection; E: the effects of different treatments on cell apoptosis and calcium ion concentration; F: the results of β-hexosaminidase determination; G: the results of histamine, TNF-α and IL-6 determination).

[0033] Figure 4 Experimental results of TSS maintaining stable mitochondrial energy metabolism (A: schematic diagram of TSS in mitochondrial energy metabolism; B: mitochondrial membrane potential results under fluorescence test; C: effects of different treatments on OCR; D: effects of TSS on basal respiratory capacity; E: effects of TSS on maximum respiratory capacity; F: results of ATP production rate; G: effects of TSS on spare respiratory capacity; H: effects of TSS on ATP production capacity).

[0034] Figure 5 The experimental results of TSS inhibiting passive cutaneous allergic reaction through intraperitoneal injection (A: schematic diagram of intraperitoneal injection of TSS into mice; B: schematic diagram of drug distribution in mice; C: Evans blue extravasation in the ear and quantitative detection results; D: HE section of mouse ear and ear thickness results; E: mast cell infiltration in mouse ear; F: Syk expression in tissue under fluorescence detection; G: Gab2 expression in tissue under fluorescence detection; H: Effects of different treatments on the expression of Syk and Gab2 in tissues; I: Effects of different treatments on leukocytes and neutrophils in mouse blood).

[0035] Figure 6The experimental results of TSS inhibiting passive cutaneous allergic reaction by transdermal administration (A: the process of TSS transdermal administration in mice; B: Evans blue extravasation in mouse ears; C: quantitative detection results of Evans blue extravasation; D: fluorescence test results of Cy5 and DAPI-Cy5; E: quantitative statistical results of tissue thickness; F: HE section of mouse ears; G: mast cell infiltration in mouse ears; H: the effect of different treatments on the expression of Syk in tissues; I: the effect of different treatments on the expression of Gab2 in tissues). DETAILED DESCRIPTION

[0036] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.

[0037] Example 1. Synthesis of Tetrahedral Framework Nucleic Acids

[0038] Four DNA single strands (S1, S2, S3, S4; sequences are shown in Table 1) were dissolved in TM buffer (10 mM Tris-HCl, 50 mM MgCl2, pH = 8.0), and the final concentration of the four DNA single strands was controlled to be 1000 nM. After being fully mixed, they were quickly heated to 95°C and maintained for 10 minutes, and then quickly cooled to 4°C and maintained for 20 minutes to self-assemble into a tetrahedral framework nucleic acid (tFNAs) solution.

[0039] Table 1. Specific sequences of the four single-stranded DNA

[0040]

[0041] Example 2: Synthesis of composite TSS

[0042] Two siRNA double strands (Gab2-siRNA and Syk-siRNA; sequences are shown in Table 2) were added to the tFNAs solution prepared in Example 1 and mixed, and the final concentration of each siRNA was controlled to be 2000 nM. The mixture was incubated at 37°C for 1 hour to obtain a siRNA-modified tetrahedral framework nucleic acid complex (abbreviated as TSS) targeting Gab2 and Syk.

[0043] Table 2. Specific sequences of two siRNA duplexes

[0044]

[0045]

[0046] The beneficial effects of the present invention are demonstrated by experimental examples below.

[0047] Experimental Example 1: Structural Characterization of Tetrahedral Framework Nucleic Acids and Complex TSS

[0048] 1. Experimental methods

[0049] High-performance capillary electrophoresis (HPCE), polyacrylamide gel electrophoresis (PAGE), dynamic light scattering (DLS), transmission electron microscopy (TEM) and atomic force microscopy (AFM) were used to verify the successful synthesis of tFNAs and the shape, particle size and zeta potential of TSS.

[0050] 2. Experimental results

[0051] Figure 1 A shows the synthesis process of TSS. Figure 1 B and 1C used high-performance capillary electrophoresis (HPCE) and polyacrylamide gel electrophoresis (PAGE) to verify the successful synthesis of tFNAs. Figure 1 The particle size of TSS detected by dynamic light scattering (DLS) was about 21.9 nm, and the potential was about -9.59 mV. Figure 1 E and 1F used transmission electron microscopy (TEM) and atomic force microscopy (AFM) to visually observe the tetrahedral morphology of TSS with side chains attached to its vertices. Figure 1 G, 1H and 1I used PAGE to verify the stability of TSS in cell lysate, serum and -4°C storage conditions. The results showed that TSS was stable at 6×10 4 It can be stable for 6 hours in the lysate of 100 cells, for 12 hours in 4% FBS at 37°C, and for one week at -4°C.

[0052] The experimental results demonstrated the successful synthesis of TSS and the good stability of the complex.

[0053] Experimental Example 2: In vitro cell experiments of tetrahedral framework nucleic acids and complex TSS

[0054] 1. Entering cells and exerting RNAi effects

[0055] 1. Experimental methods

[0056] (1) Cell culture and in vitro model preparation

[0057] RBL-2H3 cells were cultured in MEM medium containing 15% fetal bovine serum, 1% sodium pyruvate, 1% NEAA, and 1% penicillin-streptomycin, and cultured at 37°C and 5% CO2, with passage every 2-3 days. The in vitro experimental model was prepared in two steps. Sensitization: Add 0.1μg / mL anti-DNP-IgE to the cell culture medium overnight. Excitation: Remove the original culture medium, wash three times with PBS, add 10μg / mL DNP-BSA and return to the incubator for 1h. Other drug treatments should be performed after sensitization and before excitation.

[0058] (2) CCK-8 test

[0059] In order to detect the appropriate concentration of TSS, RBL-2H3 cells were cultured to the logarithmic growth phase and then treated with 1×10 5 cells were inoculated into 96-well plates at a concentration of 100 μg / mL per well. The cells were cultured in an incubator for 24 h to allow the cells to adhere. The cells were treated with different concentrations of TSS for 24 h. After removing the original culture medium, 10% CCK-8 solution (MCE, USA) was added and incubated in an incubator in the dark for 1-2 h. The absorbance at 450 nm was measured.

[0060] (3) TSS uptake by cells

[0061] The uptake of TSS by RBL-2H3 cells was evaluated by flow cytometry and confocal microscopy. RBL-2H3 cells were cultured to the logarithmic growth phase and plated at 2.5 × 10 6 The cells were inoculated into 6-well plates at a concentration of 10 cells / mL. The next day, Cy5-labeled tFNA and TSS (250 nM) were added to the serum-free medium to replace the original medium of the cells. The cells were cultured in the incubator for different time periods (6, 12, 24 h), washed 3 times with PBS, and then resuspended in PBS. The fluorescence signal in RBL-2H3 cells was detected by flow cytometry. After RBL-2H3 cells were cultured to the logarithmic growth phase, 2.5 × 10 6 The cells were inoculated into confocal dishes at a concentration of 100 cells per well. The next day, the cells were cultured for 24 h in serum-free medium containing 250 nM Cy5-labeled tFNA, Cy5-labeled Syk-siRNA, Cy3-labeled Gab2-siRNA, and TSS with the above two siRNAs. After washing the cells three times with PBS, they were stained with Hoechst solution (Solarbio, China), and the fluorescent images of the cells were taken using a confocal microscope (Olympus, Japan).

[0062] (4) Real-time fluorescence quantitative PCR (qPCR)

[0063] qPCR was used to detect the mRNA expression level of related pathways to determine whether siRNA successfully exerted RNAi effects after entering the cells. The cells were divided into six groups in total: blank group (sensitization, no stimulation), model group (sensitization, no drug treatment, stimulation), ketotifen fumarate group (sensitization, 25μg / mL ketotifen fumarate for 12h, stimulation), tFNA group (sensitization, 250nM tFNA12h, stimulation), siRNA group (sensitization, 250nM siRNA 12h, stimulation), TSS group (sensitization, 250nM TSS12h, stimulation). After treating the cells, total RNA was extracted using a total RNA extraction kit (Vazyme, China). The RNA samples were then reverse transcribed into cDNA using a reverse transcription kit (Vazyme, China). Sample mixing After Green IPCR master mix, the relative expression of target mRNA was measured using a qPCR analysis system (ABIQuantStudio 7, Thermo Fisher, USA).

[0064] (5) Western blotting (WB)

[0065] WB was used to detect the expression levels of proteins in related pathways. RBL-2H3 cells were treated as in (4) and then the cell proteins were extracted using a total protein extraction kit (KeyGen, China). The samples were mixed with 5× protein loading buffer at a ratio of 4:1 and boiled at 100°C for 10 min. Primary antibodies were used according to the previously reported protocol: anti-β-Actin (3700S, CST, USA), anti-Syk (A2123, ABclonal, China), anti-PLCγ1 (A8899, ABclonal, China), anti-phospho-PLCγ1 (AP0827, ABclonal, China), anti-Gab2 (HA500292, HUABIO, China), anti-pan-Akt (A18675, ABclonal, China), anti-phospho-Akt (AP1208, ABclonal, China). The PVDF membrane was incubated with the primary antibodies overnight at 4°C. On the second day, after washing three times with TBST, the corresponding secondary antibody (L3012, SAB, USA) was used to incubate the PVDF membrane at room temperature for 1 hour. After washing with TBST, the developer (RM00021, ABclonal, China) was added. Each membrane was detected using a chemiluminescence imaging system (Bio-Rad, USA).

[0066] (6) Immunofluorescence staining

[0067] Immunofluorescence was used to detect the localization and expression of related proteins. RBL-2H3 cells were cultured at 1×10 6 The cells were seeded at a concentration of 10 cells / mL in a confocal dish and grouped and processed as described in (4). The samples were fixed with 4% paraformaldehyde, transparentized with Triton X-100, and blocked with 5% goat serum. The samples were incubated with the following primary antibodies at 4°C overnight: anti-Syk (A2123, ABclonal, China) and anti-Gab2 (HA500292, HUABIO, China). After washing with PBS three times, the samples were incubated with 594 fluorescently labeled secondary antibodies for 1 hour. The nucleus and cytoplasm of RBL-2H3 cells were stained with DAPI and FITC-labeled phalloidin. The localization and fluorescence intensity of intracellular proteins were observed using a confocal laser microscope.

[0068] 2. Experimental results

[0069] Figure 2 A shows the process of TSS entering cells and exerting RNAi effects.

[0070] Figure 2 B was captured using a laser confocal microscope and showed two siRNAs labeled with fluorescent groups being carried into cells by tFNAs.

[0071] Figure 2 C The cell penetration efficiency of TSS was detected by flow cytometry, and there was no significant difference compared with ordinary tFNAs, and 95.4% cell penetration could be achieved within 12 hours.

[0072] Figure 2 D shows that TSS has no biological toxicity and promotes cell activity.

[0073] Figure 2 E and Figure 2 F WB showed that TSS inhibited the expression of Gab2, Syk and corresponding downstream proteins.

[0074] Figure 2 G qPCR showed that TSS inhibited the expression of Gab2, Syk and corresponding downstream genes.

[0075] Figure 2 H and Figure 2 I used immunofluorescence to verify that TSS inhibited the expression of Gab2 and Syk proteins in cells.

[0076] The above experimental results prove that TSS can carry siRNA into cells and silence the expression of Gab2 and Syk.

[0077] 2. Inhibition of RBL-2H3 cell degranulation

[0078] 1. Experimental methods

[0079] (1) Detection of RBL-2H3 cell morphological changes

[0080] RBL-2H3 cells were cultured at 1×10 6 cells / mL were inoculated into 6-well plates, and the cells were divided into six groups: blank group (sensitized, no stimulation), model group (sensitized, no drug treatment, stimulation), ketotifen fumarate group (sensitized, 25μg / mL ketotifen fumarate for 12h, stimulation), tFNA group (sensitized, 250nM tFNA for 12h, stimulation), siRNA group (sensitized, 250nM siRNA for 12h, stimulation), TSS group (sensitized, 250nM TSS for 12h, stimulation). Sensitization: 0.1μg / mL anti-DNP-IgE was added to the cell culture medium overnight. Stimulation: The original culture medium was removed, washed three times with PBS, 10μg / mL DNP-BSA was added and returned to the incubator for 1h. After cell stimulation, the cells were washed three times with PBS. Toluidine blue staining solution (Solarbio, China) was added to the first batch of samples according to the operating instructions. The cell color and morphology were observed using an optical microscope. At the same time, another batch of samples was fixed overnight at 4°C after adding 4% paraformaldehyde. A series of concentration gradient alcohols (30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 100%) were added to the samples in sequence for 15 minutes each time for dehydration. The changes in cell surface morphology were observed using a scanning electron microscope.

[0081] (2) Cell live and dead staining

[0082] The cells were stained using the Calcein / PI cell viability and cytotoxicity detection kit (Beyotime, China) according to the operating instructions. The cell fluorescence signal was observed using a fluorescence microscope. Living cells were stained with green fluorescence, and apoptotic cells were stained with red fluorescence. Cell apoptosis rate = living cells / (living cells + apoptotic cells).

[0083] (3) Calcium ion concentration detection

[0084] The cells were stained using Fluo-3, AM calcium ion concentration detection kit (Solarbio, China) according to the operating instructions. The intracellular fluorescence signal was observed using a fluorescence microscope. The fluorescence images were quantitatively analyzed using ImageJ software.

[0085] (4) β-hexosaminidase assay

[0086] RBL-2H3 cells were cultured at 5×10 5The density of each well was seeded in a 24-well plate. After 1 hour of DNP-BSA stimulation, 50 μL of cell supernatant was mixed with 50 μL of colorimetric solution (1 mM 4-Nitrophenyl N-acetyl-β-D-galactosaminide, 0,1 M Sodium Citrate Buffer, PH = 4.5) and incubated at 37 ° C for 1 hour. After 1 hour, 200 μL of stop solution (0.1 M Na2CO3 / NaHCO3, pH = 10.0) was added and the absorbance at 405 nm was detected using an enzyme reader. β-hexosaminidase release rate = (OD of the drug group - OD of the blank group) / (OD of the model group - OD of the blank group)

[0087] (5) Enzyme-linked immunosorbent assay (ELISA)

[0088] In order to detect the expression of cytokines, ELISA kits (mlbio, China) were used to detect the concentrations of histamine, TNF-α, and IL-6 in the cell supernatant.

[0089] 2. Experimental results

[0090] Figure 3 A shows that TSS can inhibit the lightening of toluidine blue staining after allergic stimulation of RBL-2H3 cells.

[0091] Figure 3 B was captured by scanning electron microscopy, showing that TSS can inhibit the irregular morphological changes of RBL-2H3 cells after allergic stimulation.

[0092] Figure 3 C and Figure 3 E shows that tFNAs and TSS can reduce the apoptosis of RBL-2H3 cells after allergic stimulation.

[0093] Figure 3 D and Figure 3 E shows that tFNAs and TSS can reduce the increase in calcium ion concentration after allergic stimulation of RBL-2H3 cells.

[0094] Figure 3 F and Figure 3 G shows that tFNAs and TSS can reduce the release of β-hexosaminidase, histamine, TNF-α and IL-6 after allergic stimulation of RBL-2H3 cells.

[0095] RBL-2H3 has biological characteristics similar to mast cells, and experimental results show that tFNAs and TSS can inhibit the degranulation of RBL-2H3 cells.

[0096] 3. Stabilize mitochondrial energy metabolism

[0097] 1. Experimental methods

[0098] (1) Mitochondrial membrane potential detection

[0099] RBL-2H3 cells were cultured at 1×10 6 The cells were seeded at a density of 10 cells / mL in a confocal dish. The cells were divided into six groups: blank group (sensitized, not stimulated), model group (sensitized, no drug treatment, stimulated), ketotifen fumarate group (sensitized, 25μg / mL ketotifen fumarate 12h, stimulated), tFNA group (sensitized, 250nM tFNA 12h, stimulated), siRNA group (sensitized, 250nM siRNA 12h, stimulated), TSS group (sensitized, 250nM TSS12h, stimulated). Sensitization: 0.1μg / mL anti-DNP-IgE was added to the cell culture medium overnight. Stimulation: The original culture medium was removed, washed three times with PBS, 10μg / mL DNP-BSA was added and returned to the incubator for 1h. After allergy stimulation, the original culture medium was removed. Mito-TrackerGreen and TMRE (Beyotime, China) were added to the cells according to the instructions and incubated in a 37℃ incubator for 30min respectively. Fluorescence signals were observed under a laser confocal microscope, and fluorescence images were quantitatively analyzed using ImageJ.

[0100] (2) ATP production rate and oxygen consumption rate detection

[0101] RBL-2H3 cells were seeded into XF24 cell culture microplates and treated according to the method (1). After allergic stimulation, the cells were washed with Seahorse buffer and incubated in a 37°C non-CO2 incubator with Agilent Seahorse XF DMEM medium containing 1 mM sodium pyruvate, 2 mM glutamine and 1 mM D-glucose for 1 h. ATP rate and OCR were measured using a Seahorse XFe24 analyzer. The program for ATP rate measurement was set to inject 1.5 μM oligomycin and 0.5 μM rotenone / antimycin A (Rot / AA). The program for OCR measurement was set to sequentially inject 1.5 μM oligomycin, 1.0 μM FCCP and 0.5 μM Rot / AA. The operation steps were strictly followed the procedures recommended by the manufacturer (Agilent, USA).

[0102] 2. Experimental results

[0103] Figure 4 A shows the process of TSS stabilizing mitochondrial energy metabolism levels.

[0104] Figure 4 B shows that tFNAs and TSS can stabilize the mitochondrial membrane potential of RBL-2H3 cells after allergic stimulation.

[0105] Figure 4 F shows that tFNAs and TSS can restore the decreased ATP production rate after allergic stimulation of RBL-2H3 cells, especially the inhibition of oxidative phosphorylation.

[0106] Figure 4 C. Figure 4 D. Figure 4 E. Figure 4 G and Figure 4 H showed that tFNAs and TSS had a good maintaining effect on the basal respiration, maximal respiration, spare respiratory capacity and ATP production capacity of RBL-2H3 cells.

[0107] The experimental results proved that tFNAs and TSS can stabilize the level of mitochondrial energy metabolism and restore the decreased mitochondrial membrane potential and metabolic changes caused by allergic stimulation.

[0108] Experimental Example 3: In vivo animal experiment

[0109] 1. Experimental methods

[0110] (1) Distribution in vivo

[0111] Male BALB / c mice, 6-8 weeks old, weighing 20-25 g, were purchased from Dossy Science (Chengdu, China). In order to study the distribution of TSS in mice, Cy5-labeled TSS was intraperitoneally injected into mice, and the fluorescence distribution was photographed using a small animal in vivo optical three-dimensional imaging system (IVIS Spectrum, Perkin Elmer, USA) at 24h, 12h, 6h, 3h, 1h, and 0h. In order to study the local transdermal effect of TSS, Cy5-labeled TSS was mixed with an equal volume of cream for later use. The ointment was applied to the mouse ears, and samples were collected at 24h, 12h, 6h, and 0h and fixed in 4% paraformaldehyde for 24h. The ears were then frozen in liquid nitrogen and fixed with embedding glue to make sections. The nuclei in the sections were stained with DAPI, and the sections were scanned using a full slide scanner (VS200, Olympus, Japan).

[0112] (2) Passive skin allergic reaction

[0113] Anti-DNP-IgE sensitization is a known method to construct a type I hypersensitivity reaction model.

[0114] Male BALB / c mice were raised in an SPF environment for one week and then divided into the following 8 groups: blank group, model group, tFNAs group, siRNA group, ketotifen fumarate injection group, TSS injection group, ketotifen fumarate topical group, TSS topical group (n=3). After ether anesthesia, 0.5 μg anti-DNP-IgE was injected intradermally into the ears of mice for sensitization. 24 hours later, 0.5 mg DNP-BSA (containing 1% Evans blue) was injected into the tail vein of mice to induce allergy. 6 h before the challenge, mice in the blank group (200 μL saline), model group (200 μL saline), tFNAs group (200 μL 1000 nM tFNAs), siRNA group (200 μL 1000 nM siRNA), ketotifen fumarate injection group (200 μL 20 μg / g ketotifen fumarate), and TSS injection group (200 μL 1000 nM TSS) were injected intraperitoneally. 24 h before the challenge, ketotifen fumarate (10 μg / g mixed in cream) and TSS (mixed with cream in equal volume) were applied to the ears of mice in the ketotifen fumarate topical group and TSS topical group, respectively. 1 h after the allergic challenge, the mice were euthanized and samples were collected.

[0115] (3) Evans blue leakage test

[0116] Take photos to record the Evans blue exudation in the mouse ears. Collect the ears of mice in each group and dry the ears of the same size at 60℃ for 24h. Cut the ears into pieces and put them into 1mL formamide, incubate them in a water bath at 85℃ for 2h, centrifuge them at 3000rpm for 15min, and detect the absorbance of the supernatant at 620nm.

[0117] (4) Histological examination

[0118] The ears of mice in each group were collected and immersed in 4% paraformaldehyde. The tissue samples were dehydrated, embedded in paraffin, and then made into sections. The samples were stained with HE and toluidine blue to observe the edema of the tissue and the infiltration of mast cells. In addition, the sections were immunofluorescently stained to evaluate the expression of Syk and Gab2 proteins in the tissue. The thickness and fluorescence intensity of each sample were the average values ​​of the measurements of three random sites in the sample.

[0119] (5) Routine blood test

[0120] Blood was collected from the eyeballs of mice, placed in EDTA anticoagulant tubes and mixed thoroughly, and the various cells in the blood were detected using a hematology analyzer.

[0121] 2. Experimental results

[0122] Figure 5 A shows the process of suppressing passive cutaneous anaphylaxis by intraperitoneal injection of TSS.

[0123] Figure 5 B shows that 6 hours after intraperitoneal injection of TSS, the drug can be distributed throughout the mouse body.

[0124] Figure 5 C shows that tFNAs and TSS effectively inhibited the extravasation of Evans blue in the ear.

[0125] Figure 5 D shows that tFNAs and TSS effectively inhibited edema in the mouse ears.

[0126] Figure 5 E shows that tFNAs and TSS effectively reduce mast cell infiltration in mouse ears.

[0127] Figure 5 F. Figure 5 G and Figure 5 H shows that tFNAs and TSS inhibited the expression of Syk and Gab2 in tissues.

[0128] Table 3. Expression of Syk after treatment in different experimental groups

[0129]

[0130] As can be seen from Table 3, the expression of Syk was reduced after treatment with Ketotifen, siRNA, tFNAs and TSS. Further comparison of the percentage of Syk expression reduction after siRNA, tFNAs and TSS treatment relative to the Model group in Table 3 showed that the effect of reducing Syk expression after TSS treatment was higher than the sum of the effects of reducing Syk expression after siRNA treatment and tFNAs treatment, indicating that TSS played a synergistic effect in reducing Syk expression.

[0131] Table 4. Expression of Gab2 after treatment in different experimental groups

[0132]

[0133]

[0134] As can be seen from Table 4, the expression of Gab2 was reduced after treatment with Ketotifen, siRNA, tFNAs and TSS. Further comparison of the percentage of Gab2 expression reduction after siRNA, tFNAs and TSS treatment relative to the Model group in Table 4 showed that the effect of reducing Gab2 expression after TSS treatment was higher than the sum of the effects of reducing Gab2 expression after siRNA treatment and tFNAs treatment, indicating that TSS played a synergistic effect in reducing Gab2 expression.

[0135] Figure 5 I showed that tFNAs and TSS reduced the increase of white blood cells, especially neutrophils, in the blood of mice.

[0136] Figure 6 A shows the process of TSS transdermal administration to inhibit passive cutaneous allergic reactions.

[0137] Figure 6 B shows that TSS effectively inhibits Evans blue extravasation in the ear.

[0138] Figure 6 C is the quantitative detection of Evans blue extravasation, and the results show that TSS effectively inhibits the extravasation of Evans blue in the ear.

[0139] Figure 6 D shows that 24 h after topical application of TSS, drug fluorescence can be largely observed in the tissue.

[0140] Figure 6 E is right Figure 6 F. Quantitative statistics of tissue thickness. The results showed that TSS effectively inhibited edema in the mouse ears.

[0141] Figure 6 F is the HE section of the mouse ear, where it can be observed that TSS effectively inhibits the edema of the mouse ear.

[0142] Figure 6 G shows that TSS effectively reduces mast cell infiltration in mouse ears.

[0143] Figure 6 H and Figure 6 I shows that TSS inhibited the expression of Syk and Gab2 in tissues.

[0144] The experimental results show that the single administration of tFNAs of the present invention can effectively inhibit type I hypersensitivity reaction, and the complex TSS obtained by further modifying siRNA targeting Gab2 and Syk on the basis of tFNAs can also effectively inhibit type I hypersensitivity reaction, and the complex TSS plays a synergistic role in inhibiting type I hypersensitivity reaction.

[0145] In summary, the present invention provides a drug for treating type I hypersensitivity. The tetrahedral framework nucleic acid of the present invention can effectively inhibit mast cell degranulation, stabilize the level of mitochondrial energy metabolism, restore the reduction of mitochondrial membrane potential and metabolic changes caused by allergic stimulation, and effectively inhibit type I hypersensitivity in vivo. The present invention further modifies siRNA targeting Gab2 and Syk on the basis of the tetrahedral framework nucleic acid to obtain the complex TSS. The complex TSS can stabilize mitochondrial energy metabolism, inhibit the efflux of calcium ions into the mitochondria, inhibit the occurrence of mast cell degranulation, and play a role in inhibiting type I hypersensitivity. It is particularly noteworthy that the complex TSS plays a synergistic role in inhibiting type I hypersensitivity. The tetrahedral framework nucleic acid and the complex TSS of the present invention are not only simple to synthesize and stable in structure, but also have broad application prospects in the preparation of drugs for preventing and / treating type I hypersensitivity.

Claims

1. A tetrahedral framework nucleic acid, It is characterized in that It is self-assembled by four DNA single strands, and the sequences of the four DNA single strands are shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 respectively.

2. A method for preparing the tetrahedral framework nucleic acid according to claim 1, It is characterized in that The method comprises the following steps: mixing four DNA single strands, heating them for reaction, and then cooling them for reaction, so as to obtain a tetrahedral framework nucleic acid.

3. The method according to claim 2, It is characterized in that The heating reaction temperature is 80-100°C and the time is 5-15min; The temperature of the cooling reaction is 0-10°C and the time is 10-30min; Preferably, the heating reaction temperature is 95°C and the time is 10 minutes; The temperature of the cooling reaction is 4°C and the time is 20 minutes.

4. A tetrahedral framework nucleic acid complex, It is characterized in that The invention is a product prepared by using an agent for inhibiting mast cell degranulation and the tetrahedral framework nucleic acid according to any one of claims 1 to 3 as raw materials.

5. The tetrahedral framework nucleic acid complex according to claim 4, It is characterized in that The agent for inhibiting mast cell degranulation is an agent for inhibiting Gab2 and / or Syk expression.

6. The tetrahedral framework nucleic acid complex according to claim 5, It is characterized in that The reagent for targeted inhibition of Gab2 expression is a siRNA for targeted inhibition of Gab2 expression, wherein the siRNA for targeted inhibition of Gab2 expression is formed by two single strands having sequences as shown in SEQ ID NO.5 and SEQ ID NO.6 respectively through base complementary pairing; The reagent for targeted inhibition of Syk expression is siRNA for targeted inhibition of Syk expression, and the siRNA for targeted inhibition of Syk expression is formed by two single strands with sequences as shown in SEQ ID NO.7 and SEQ ID NO.8 respectively through base complementary pairing.

7. The tetrahedral framework nucleic acid complex according to any one of claims 4 to 6, It is characterized in that The reagent for inhibiting mast cell degranulation is a reagent for targeted inhibition of Syk expression and a reagent for targeted inhibition of Gab2 expression. The molar ratio of the reagent for targeted inhibition of Syk expression, the reagent for targeted inhibition of Gab2 expression, and the tetrahedral framework nucleic acid is 1:1:(0.1-1), preferably 1:1:0.

5.

8. A method for preparing the tetrahedral framework nucleic acid complex according to any one of claims 4 to 7, It is characterized in that The method comprises the following steps: mixing a reagent for inhibiting mast cell degranulation with a tetrahedral framework nucleic acid and reacting the mixture to obtain a tetrahedral framework nucleic acid complex.

9. Use of the tetrahedral framework nucleic acid according to claim 1 or the tetrahedral framework nucleic acid complex according to any one of claims 4 to 7 in the preparation of a medicament for preventing and / or treating type I hypersensitivity reaction.

10. The use according to claim 9, It is characterized in that The drug is a drug that inhibits mast cell degranulation.

Citation Information

Patent Citations

  • Medicine for preventing oxidative stress of retinal ganglion cells and wet macular degeneration

    CN112007044A

  • DNA tetrahedron compound and application thereof in preparation of medicine for treating psoriasis

    CN116870174A

  • Tetrahedral framework nucleic acid targeting RAGE and application of tetrahedral framework nucleic acid

    CN117106775A

  • Application of tetrahedral framework nucleic acid-curcumin compound in preparation of medicine for preventing and / or treating diabetic osteoporosis

    CN117323438A

  • Methods for modulating MHC-i expression and immunotherapy uses thereof

    WO2021247540A1